Compare DexCom, Inc. (DXCM) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Health Care Select Sector SPDR Fund — how do they compare? DexCom, Inc. trades at $77.1 (market cap $28.06B), while Health Care Select Sector SPDR Fund trades at $161.46. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | XLV | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $164.48 |
52-Week Low | $54.84 | $129.01 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
XLV trades at $161.47, up 2.01% with a bullish technical signal from moving averages. The healthcare ETF benefits from State Street's upgraded sector outlook and strong performance from holdings like Johnson & Johnson. Technical indicators show support at $156-158 with resistance at $159-161, while RSI readings suggest neutral momentum.
The outlook remains positive as healthcare gains favor for defensive qualities amid market volatility. Key risks include patent expirations and regulatory pressures, but diversified exposure and innovation in biotech/pharma support long-term growth potential. Analyst sentiment favors healthcare for stability and innovation-driven returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
